Some RCTs suggested that this combination therapy improved clinical effectiveness and reduce adverse events,[18,19] but some found no significant changes in the relevant outcomes.[27,28,29,30,31,32] The effects of CKI combined with PBC for patients with stage III/IV NSCLC have never been systematically evaluated. The gene discussed is CHKA; the disease is non-small cell lung carcinoma.